The global oncolytic virus therapies market size is expected to reach USD 609.7 Million at a steady CAGR of 26.2% in 2028, according to latest analysis by Emergen Research. Rise in prevalence of cancer, increase in number of clinical trials and investment in research & development for cancer therapies are driving the growth of oncolytic virus therapies market.
Oncolytic virus is a virus which infects and kills cancer cells and as these cancer cells are destroyed by oncolysis, they release new infectious particles which destroy remaining tumor. Cancer mortality rate is 158.3 per 100,000 people per year. Estimated national expense for cancer in the U.S. was USD 150.8 billion in 2018. This cost is likely to increase as population ages and need for development of new effective therapies will fuel oncolytic virus therapies market growth.
The investigative approach applied for the extensive analysis of the sale, gross margin and profit generated by the industry are presented through resources including tables, charts, and graphic images. Importantly, these resources can be easily integrated or used for preparing business or corporate presentations.
You Can Download Free Sample PDF Copy of Oncolytic Virus Therapies Market at https://www.emergenresearch.com/request-sample/704
Some Key Highlights in the Report
In January 2021, Enara Bio and Boehringer Ingelheim announced a strategic collaboration and licensing agreement for R&D of novel targeted cancer immunotherapy. The new collaboration combines Boehringer’s approach to treat cancer through pairing science with innovative platforms such as oncolytic virus and cancer vaccines, with Enara’s expertise in cancer antigen identification.
Breast cancer is among the second most diagnosed cancer across the globe and current treatments are insufficient to cure metastatic breast cancer often associated with severe side effects which destroys patient’s quality of life. Oncolytic virus therapies has emerged as a relevant tool to target different kinds of cancer such as breast cancer. For instance, Pelareorep is an unmodified and intravenously delivered oncolytic virus which primes an immune response among patients with breast cancer.
Rise in number of research institutes for development of effective therapies and drugs to treat and study cancer, particularly in developing countries, is driving the growth of cancer research institute segment. Increased investment by private and government sectors into these institutions is driving segment growth.
North America accounted for the largest revenue share in 2020. The U.S. is the primary contributor and is expected to witness high growth due to the large amount of funding by the private firms and government for clinical trials. Other factors driving the oncolytic virus therapies market are an increase in research and development initiatives to develop therapeutic options for chronic diseases, easy approval for clinical trials, and availability of highly sophisticated research infrastructure.
Key players in the market include Oncolytics Biotech, Inc., Amgen Inc., Sorrento Therapeutics, Inc., Transgene SA, Daiichi Sankyo Company, Limited, Shanghai Sunway Biotech Co., Ltd., Takara Bio Inc., PsiOxus Therapeutics, SillaJen, Inc., and ViroCure.
Get access to FREE Sample PDF Copy of Oncolytic Virus Therapies Market at https://www.emergenresearch.com/request-sample/704
Virus Type Outlook (Revenue, USD Million; 2018–2028)
Genetically Engineered Oncolytic Viruses
Herpes Simplex Virus
Oncolytic Wild-Type Viruses
Newcastle Disease Virus
Vesicular Stomatitis Virus
Application Outlook (Revenue, USD Million; 2018–2028)
End-use Outlook (Revenue, USD Million; 2018–2028)
Cancer Research Institute
Proceed to buy@ https://www.emergenresearch.com/select-license/704
Key questions answered in the report
What will be the market size in terms of value and volume in the next five years?
Which segment is currently leading the market?
In which region will the market find its highest growth?
Which players will take the lead in the market?
What are the key drivers and restraints of the market’s growth?
The report segments the Oncolytic Virus Therapies market on the basis of geography, end-user, end-use, product application, type, share, growth rate and size to reveal where the industry will be in the coming years. The researchers assessing the industry have included the details about the recent decisions and events such acquisition and mergers, collaborations, product launch and investments. Important decisions connected with such events come handy for business owners when positioning their brands in the global market and finalizing the marketing strategies.
Table of Content
Chapter 1. Methodology & Sources
1.1. Market Definition
1.2. Research Scope
1.4. Research Sources
1.4.3. Paid Sources
1.5. Market Estimation Technique
Chapter 2. Executive Summary
2.1. Summary Snapshot, 2019-2027
Chapter 3. Key Insights
Chapter 4. Oncolytic Virus Therapies Market Segmentation & Impact Analysis
4.1. Oncolytic Virus Therapies Market Material Segmentation Analysis
4.2. Industrial Outlook
4.2.1. Market indicators analysis
4.2.2. Market drivers analysis
184.108.40.206. Stringent environmental regulations
220.127.116.11. Rising need to reduce bacterial or algal contamination in water systems
18.104.22.168. Increasing demand for biocides for municipal water treatment
4.2.3. Market restraints analysis
22.214.171.124. Fluctuating prices of raw material
126.96.36.199. Present challenging economic conditions due to the pandemic
4.3. Technological Insights
4.4. Regulatory Framework
4.5. Porter’s Five Forces Analysis
4.6. Competitive Metric Space Analysis
4.7. Price trend Analysis
4.8. Covid-19 Impact Analysis
Chapter 5. Oncolytic Virus Therapies Market By Application Insights & Trends, Revenue (USD Million), Volume (Kilo Tons)
Chapter 6. Oncolytic Virus Therapies Market By Product type Insights & Trends Revenue (USD Million), Volume (Kilo Tons)
Chapter 7. Oncolytic Virus Therapies Market Regional Outlook
Chapter 8. Competitive Landscape